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Abstract
Background: Plasmids are being reconsidered as viable vector alternatives to viruses for gene
therapies and vaccines because they are safer, non-toxic, and simpler to produce. Accordingly,
there has been renewed interest in the production of plasmid DNA itself as the therapeutic end-
product of a bioprocess. Improvement to the best current yields and productivities of such
emerging processes would help ensure economic feasibility on the industrial scale. Our goal,
therefore, was to develop a stoichiometric model of Escherichia coli metabolism in order to (1)
determine its maximum theoretical plasmid-producing capacity, and to (2) identify factors that
significantly impact plasmid production.
Results: Such a model was developed for the production of a high copy plasmid under conditions
of batch aerobic growth on glucose minimal medium. The objective of the model was to maximize
plasmid production. By employing certain constraints and examining the resulting flux distributions,
several factors were determined that significantly impact plasmid yield. Acetate production and
constitutive expression of the plasmid's antibiotic resistance marker exert negative effects, while
low pyruvate kinase (Pyk) flux and the generation of NADPH by transhydrogenase activity offer
positive effects. The highest theoretical yield (592 mg/g) resulted under conditions of no marker or
acetate production, nil Pyk flux, and the maximum allowable transhydrogenase activity. For
comparison, when these four fluxes were constrained to wild-type values, yields on the order of
tens of mg/g resulted, which are on par with the best experimental yields reported to date.
Conclusion: These results suggest that specific plasmid yields can theoretically reach 12 times
their current experimental maximum (51 mg/g). Moreover, they imply that abolishing Pyk activity
and/or transhydrogenase up-regulation would be useful strategies to implement when designing
host strains for plasmid production; mutations that reduce acetate production would also be
advantageous. The results further suggest that using some other means for plasmid selection than
antibiotic resistance, or at least weakening the marker's expression, would be beneficial because it
would allow more precursor metabolites, energy, and reducing power to be put toward plasmid
production. Thus far, the impact of eliminating Pyk activity has been explored experimentally, with
significantly higher plasmid yields resulting.
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Background
Microorganisms such as Escherichia coli are routinely used
for producing recombinant proteins. The recombinant
gene of interest is usually carried on a high copy number
plasmid in order to boost gene dosage and, ultimately,
process yield. While the usual view of the plasmid's role is
simply as the vehicle for recombinant protein expression,
the appeal of plasmids as gene therapy vectors has recently
sparked interest in the production of plasmid DNA itself
as the process end-product. Once thought inferior to viral
vectors, plasmids are being reconsidered as viable vector
alternatives for gene therapies and vaccines because they
are safer, non-toxic, simpler to produce, and can accom-
modate larger inserts. In fact, of the 261 gene therapy clin-
ical trials approved from 2006–08, 22% employed a
plasmid DNA vector [1].
To date, efforts aimed at achieving high upstream plasmid
yields have focused primarily on the optimization of fer-
mentation conditions (e.g. medium design, cultivation
mode, feeding strategy, pH or DO control), and/or on the
usage of a plasmid containing a high copy number, tem-
perature-sensitive origin of replication (ori) [2-8].
Designed media typically contain several or all amino
acids and/or nucleosides in addition to minimal salts and
a carbon source such as glycerol, which confers a slow
growth rate [4-7]. Reduced growth rate, in turn, has been
linked to elevated copy numbers [9]. In E. coli, pUC-based
plasmids are the norm. A mutation in its RNA primer and
elimination of the rop (repressor of primer) gene result in
much higher copy numbers than those observed for its
originator, pBR322 [10]. Moreover, its high copy pheno-
type can be bolstered several-fold further upon tempera-
ture-shift (e.g. ≤ 37°C to 42°C) [2,5,7,8,10,11]. The best
yield reported thus far employing combinations of such
techniques has been 51 mg/g [8], and the highest produc-
tivity has been 36 mg/L/h [5].
Unlike other therapeutic products such as streptokinase,
vaccines must be produced and administered in popula-
tion- as opposed to subpopulation-scale quantities. For
100 million doses at 1 mg per dose [11], and 10 different
vaccine products, about 100 million liter-hours of pro-
ductive capacity would now be required. Clearly at such a
scale, a 10-fold reduction or more in required capacity
would favorably impact the economics. Additionally, it
would be less challenging to coordinate the production of
multiple vaccine products. Apart from scale, the US FDA
currently recommends that, in addition to proteins, RNA,
and cell envelope components, both genomic DNA and
non-supercoiled plasmid isoforms should be considered
as contaminants [12,13]. Thus, commencing purification
with a higher relative abundance of efficacious material
would lessen the impact of downstream losses and lower
the contaminant level per mass of isolated product. The
considerations of scale and purity indicate that it would
be useful to determine what the maximum theoretical
plasmid yield is for a given set of nutritional conditions,
and compare that to current yields.
To estimate what the maximum yield might be for aerobic
growth on glucose minimal medium, a simple carbon bal-
ance can be performed. The yield determined in such a
manner will not, however, consider any constraints that
can arise when nested metabolic networks traffic carbon
from inputs (glucose, CO2) to products (biomass, CO2,
acid by-products, plasmid, antibiotic resistance marker for
plasmid selection). This simple calculation for a model
pUC-based plasmid (pGFPuv, 3.3 kb) shows that yields of
742 mg/g (33,000 copies/cell) might be attained when
30% of glucose carbon is released as CO2 and there is no
marker or acetate production (see Appendix). This theo-
retical yield is 15-fold greater than the best that has been
achieved experimentally to date [8]. Because the currently
employed strategies do not approach the estimated theo-
retical yield, a metabolic flux analysis might help eluci-
date why this is the case. Such an analysis would reveal
whether constraints arise and/or suboptimal metabolic
trafficking detracts from the observed value of the yield,
given that the negative control over replication is not lim-
iting.
Our goal, therefore, was to develop a stoichiometric
model of E. coli metabolism for batch aerobic growth on
glucose minimal medium, with the model's objective
being to maximize plasmid production. Such models
have been developed before for E. coli and other microor-
ganisms, like Bacillus subtilis, to assess the production
capacity for amino acids and nucleotides by E. coli [14] or
folic acid by B. subtilis [15]. Not only do such models
allow for a more appropriate determination of the maxi-
mum theoretical yield for a given set of conditions, but
they also reveal how carbon should traffic through the
metabolic network to achieve the ultimate yield. This
information is particularly useful because these optimal
carbon flux distributions can be examined to rationally
identify gene candidates whose mutation or up/down-reg-
ulation might positively impact product yield. Thus,
results from this study could serve as guides for engineer-
ing host strains for plasmid production.
Using flux analysis, we determined the factors that signif-
icantly impact plasmid production, the optimal flux dis-
tribution, and the theoretical maximum yield of plasmid
production. This paper describes the key factors found.
First, as one would expect, both the production of acetate
and the constitutive expression of the plasmid's antibiotic
resistance marker exert negative effects. Interestingly, nil
pyruvate kinase (Pyk) flux and the generation of NADPH
by nicotinamide nucleotide transhydrogenase activityMicrobial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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were found to offer yield-enhancing effects. The highest
theoretical yield (592 mg/g) resulted when the optimal
flux distribution showed no marker or acetate production,
nil Pyk flux, and the maximum allowable transhydroge-
nase activity. These results suggest that specific plasmid
yields can theoretically reach 12 times their current exper-
imental maximum. Moreover, they imply that Pyk dele-
tion and/or transhydrogenase up-regulation would be
useful strategies to implement when designing host
strains for plasmid production. After presenting these
results, we describe the results of published experiments
[16] that were aimed at pursuing some of the findings
from the analysis. The experimental results indicate that
one advantageous mutation identified by the analysis,




Figure 1 shows the metabolic network that was subjected
to analysis. Glycolysis, the hexose monophosphate
(HMP) pathway, and the tricarboxylic acid (TCA) cycle
comprise the bulk of the reactions. Others include the
uptake of glucose via the phosphotransferase system
(PTS), the potential generation of acid by-products (ace-
tate, lactate, and succinate), and two anaplerotic reactions
(phosphoenolpyruvate carboxylase, Ppc; malic enzyme,
Mez). Known biochemistry was used to establish the stoi-
chiometry and directionality of these reactions [17,18].
Biomass is produced from precursor metabolites (Fig. 1,
large blue arrows) according to the composition specified
by Neidhardt et al. [17]. Because the goal of this work was
to determine the optimum flux distribution for maximum
plasmid production, reactions were included for the syn-
thesis of deoxyribonucleoside triphosphate (dNTP) build-
ing blocks from precursor metabolites, the synthesis of the
model plasmid (pGFPuv; Clontech, GenBank #U62636)
from the appropriate numbers of dNTPs, and for the con-
stitutive expression of the antibiotic resistance marker
contained on that plasmid (i.e. β-lactamase; Bla). Assum-
ing that 1.36 mol ATP are required per mol dNTP for
polymerization [17], the plasmid reaction is:
The stoichiometry used for each of the four dNTPs from
precursors was that of Neidhardt et al. [17], with the
demand for single carbon units satisfied by the synthesis
of serine as described by the authors. The overall stoichi-
ometry of the Bla reaction was established using its amino
acid composition, 4.324 mol ATP/mol amino acid for
polymerization, and accounting for single carbon units as
serine [17]. The net reaction from precursors is as follows:
The production of biomass, plasmid, and Bla require
energy and reducing power. Aside from substrate-level
phosphorylation, ATP can be produced via electron trans-
port and oxidative phosphorylation. For P/O ratios, we
assumed that 1 mol FADH2 generates 1 mol ATP, and 1
mol NADH generates 2 mol ATP. NADH and NADPH are
produced by the central metabolic pathways, and the
model also contains a reversible transhydrogenase reac-
tion that allows for their interconversion.
Model Definition and Solution Method
At steady state (i.e. balanced exponential growth), the m
reactions and n metabolites of a given reaction network
collectively define a set of linear mass balance equations
that can be formulated as:
where S is the n × m stoichiometric matrix, r is an m × 1
vector of the unknown metabolic reaction rates or fluxes,
and b is an n × 1 vector of the rates of metabolite con-
sumption or generation.
The objective function for all optimizations carried out in
this work was to maximize plasmid production:
The mass balances from Equation (3) were employed as
constraints, and bounds were imposed on irreversible
fluxes to ensure that their values remained non-negative.
The drain on a given precursor metabolite for biomass
synthesis (Fig. 1, large blue arrows) was specified as an
equality constraint by using the biomass composition of
Neidhardt et al. [17] and multiplying its amount (mmol/
g) by an assumed specific growth rate (μ) of 0.74 h-l. The
amount of NADPH needed for biomass synthesis was
fixed at 18.225 μ mmol/g/h, while the required ATP was
defined as a greater-than-or-equal-to constraint (41.223 μ
mmol/g/h) [17]. With the constraint formulated in this
manner, the model is guaranteed to generate at least the
amount of energy needed to produce macromolecular
building blocks from precursor metabolites as well as that
required for polymerization.
Carbon is supplied to the network exclusively from glu-
cose or CO2 (Fig. 1, boxed). Glucose uptake was limited to
an upper bound based on a typical biomass yield of 0.35
g/g glucose for aerobic growth in minimal medium con-
taining glucose concentrations that are high enough to
permit acetate excretion [19]. Because the objective was
1728 1728 1609 1609 9076  dATP  dTTP  dCTP  dGTP  ATP plasmid ++++ →
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Metabolic reaction network of plasmid production in E. coli for aerobic growth on glucose minimal medium Figure 1
Metabolic reaction network of plasmid production in E. coli for aerobic growth on glucose minimal medium. 
Points of carbon entry are boxed. Points of carbon exit are circled except for drains on precursor metabolites for biomass syn-
thesis, which are denoted in blue and by large shaded arrowheads. Double-ended arrows represent potentially reversible reac-
tions, with the larger arrowhead depicting the net direction. Key fluxes discussed in the text are labeled as ri. Specific details on 
reaction stoichiometries can be found in the Methods, and abbreviations are defined in the Abbreviations section.Microbial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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always to maximize plasmid production, this upper
bound was adopted by every model posed in this study in
order to supply the maximum allowable carbon to the sys-
tem. Further, it agrees well with reported experimental
glucose uptake under the growth conditions considered
[20]. In addition to biomass, carbon was permitted to be
extracted from the network as CO2, acid by-products, plas-
mid, and/or Bla (Fig. 1, circled).
Bla production was linearly coupled to plasmid synthesis
as follows:
where α, whose units are mol Bla/mol plasmid, represents
the product of transcriptional (number of transcripts per
gene) and translational (number of ribosomes per tran-
script in a polysome) activities. Thus, it reflects the bilin-
ear combination of promoter strength and ribosome
binding/content. To put α into a quantitative perspective,
consider its value for fully activated LacZ production. A
value of 1838 (about 56 transcripts per gene and about 32
ribosomes per transcript) was determined in a modeling
study [21], which was reported to be in good agreement
with experimental data [22]. Variation of α and relaxation
of Equation (5) to an inequality constraint based on the
availability of protein synthesis machinery is described in
the text for particular modeling aims. Other key fluxes that
were either constrained or unconstrained in order to
explore particular flux trafficking scenarios are racetate, rPyk,
and rtranshydrogenase (Fig. 1). The first two of these fluxes can
be assumed to be unconstrained unless specified to the
contrary, whereas rtranshydrogenase was constrained to be zero
unless otherwise noted.
To solve the optimization problems posed in this work,
the model was constructed in GAMS, and the recursive
mixed-integer linear programming algorithm described
by Lee et al. [23] was employed.
Results
Optimal Flux Distribution for Maximum Plasmid 
Production
In order to determine the optimum flux distribution for
maximum plasmid production, the model was solved for
α = 0 in Equation (5). This α-value corresponds to a situ-
ation where nil antibiotic resistance marker production is
allowed to occur. This case provides the upper bound
value of the maximal yield, which represents the horizon
for emerging selection techniques that do not rely on high
levels of constitutive antibiotic resistance expression [24-
26]. Later, the effect of nonzero α is considered.
Figure 2 (top) shows the optimal flux distribution. The
maximum theoretical plasmid yield predicted is 502 mg/
g. No input carbon is wasted in the formation of acidic by-
products (i.e. acetate, lactate, or succinate); hence, all car-
bon not consumed for biomass synthesis is put towards
plasmid production or released as CO2. Note that this
yield does not perfectly match that predicted by the sim-
ple carbon balance (742 mg/g, Appendix). That number,
however, was calculated assuming a value of 30% for the
fraction of input carbon given off as CO2, whereas the
model's stoichiometry provides a value of 36.8%. Interest-
ingly, the optimal solution results when Pyk flux is nil.
Since this flux is nonzero in wild-type E. coli, it may repre-
sent a site where targeted mutation could prove beneficial
when designing host strains for maximal plasmid produc-
tion. The impact of Pyk will be further examined below,
and experimental results concerning Pyk-deficient E. coli
will be described in the Discussion section.
Effects of Antibiotic Resistance Marker Production
Because many current plasmids rely on the constitutive
production of an antibiotic resistance marker for selection
(e.g. Bla), some fraction of the available precursor metab-
olites, energy, and reducing power must be consumed to
synthesize this protein. Therefore, the more marker pro-
duced, the less that these resources are available for plas-
mid production. Indeed, markers are usually produced at
levels far exceeding those that are necessary for plasmid
maintenance and selection, with levels at 20% of total cel-
lular protein not uncommon in the case of high copy plas-
mids [27,28]. Aside from creating a metabolic burden,
excess marker synthesis can substantially impact down-
stream purification due to the hyper-sensitivity of some
patients to product contamination by marker protein
[29].
To gauge the extent to which concomitant marker produc-
tion negatively impacts plasmid yield, the model was
solved for many different values of α in Equation (5). Fig-
ure 3A (black solid line) shows how maximum plasmid
yield varies with α and the corresponding amount of Bla
produced (expressed as a percentage of total protein). As
expected, as α and thus Bla production increase, the plas-
mid yield decreases. The decrease is remarkably steep for
the lowest values of α. By α = 250, for example, the marker
constitutes roughly 44% of total protein, and its drain on
resources diminishes plasmid-producing capacity by over
75% (502 mg/g for α = 0 to 112 mg/g).
Figure 2 (middle) shows the flux distribution for this α =
250 case. This value of α corresponds to a situation where
Bla's promoter strength is about one-third that of the lac
promoter (23 transcripts per gene) [21,22], and the
number of bound ribosomes per transcript is about 11
based on Bla's message length and a typical ribosome
spacing distance [29]. As with the α = 0 case, no carbon is
wasted in the form of acid by-products, and the Pyk flux is
rr Bla plasmid = α (5)Microbial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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Optimal carbon flux distributions for maximum plasmid production in E. coli Figure 2
Optimal carbon flux distributions for maximum plasmid production in E. coli. In all three distributions,rtranshydrogenase 
was constrained to zero, while racetateand rPyk were not constrained. Distributions vary by their assigned value of α in Equation 
(5) and/or whether or not a limit was imposed on Bla production. Top:α = 0. Middle:α = 250; unlimited Bla production. Bot-
tom:α = 250; Bla production limited to 20% of total protein (Equation (7), f = 0.20). For simplicity, the network in Fig. 1 has 
been condensed and fluxes (mmol/g/h) have been expressed as % of glucose uptake, except rBla (expressed as % of total pro-
tein) and rplasmid (expressed as yield in mg/g). The production of lactate and succinate have also been omitted, as these fluxes 
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zero. In contrast to the α = 0 case, HMP and Ppc fluxes are
greater, whereas glycolytic and TCA cycle fluxes are less-
ened in order to provide the appropriate balance of pre-
cursors, energy, and reducing power for both plasmid and
Bla production (see also Fig. 3E & Fig. 3F).
Effects of Imposing a Limit on Marker Production
Because the marker represents such a large fraction of total
protein even at modest values of α (Fig. 3A), we also con-
sidered what would happen to plasmid production if the
cell had an upper bound for marker production. This ceil-
ing could be set by a limitation in the transcriptional and/
or translational machinery, such as a limited availability
of free ribosomes. If this limit existed and was reached,
plasmid replication could continue while marker synthe-
sis had hit its ceiling, a phenomenon which has been
observed experimentally [30]. In this case, marker synthe-
sis would no longer occur with linear dependence on plas-
mid synthesis as dictated by Equation (5), despite the fact
that there will always be a one-for-one increase in marker
genes with plasmids. Therefore, the ultimate burden that
marker production imposes on plasmid yield would be
lessened, and more resources would be available for use in
plasmid production. Thus, this calculation allows for the
maximal plasmid yield to be assigned a range, where a
tight or decoupled relationship between gene dosage and
marker level establishes a lower or upper bound, respec-
tively.
Implementing such decoupling in the model is straight-
forward. When one is interested in limiting Bla produc-
tion to some fraction (f) of total protein, the
Maximum plasmid yield and other key fluxes as a function of α Figure 3
Maximum plasmid yield and other key fluxes as a function of α. (A-C) Maximum plasmid yield for different racetate and 
rPyk scenarios, variable limits on Bla production, and rtranshydrogenase = 0. The fluxes racetate and rPyk were: (A) unconstrained, but 
adopted values of zero, (B) set to JM101 (wild-type) values, or (C) fixed at PB25 (Pyk-deficient) values. Solid lines: No upper 
limit imposed on Bla production. Dashed lines: Bla production limited to selected percentages of total protein. Yield decreases 
as a function of promoter strength α along a solid line if Bla production is unconstrained. When Bla production is limited to a 
particular percentage, the yield decreases along a solid line until it becomes independent of α at its respective flat dashed line. 
(D) Effect of transhydrogenase activity on plasmid yield. Solid lines: Redrawn from (A-C) for comparison where unconstrained 
(black), PB25 (red), and JM101 (blue) values for racetate and rPyk are assumed, and rtranshydrogenase = 0. Dashed lines:Increased maxi-
mum plasmid yield for unconstrained (black), PB25 (red), and JM101 (blue) cases when rtranshydrogenase > 0 per Equation (10). (E) 
HMP:glycolysis flux ratio when rtranshydrogenase = 0 (solid lines) or when rtranshydrogenase > 0 per Equation (10) (dashed lines). Con-
trasted are the unconstrained (black), PB25 (red), and JM101 (blue) cases. (F) Ppc flux as % glucose uptake when rtranshydrogenase = 
0 (solid lines) or > 0 (dashed lines). Cases compared and color coding as in (D) and (E).Microbial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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stoichiometries of protein biomass and Bla can be used to
formulate an expression for f. For example, biomass con-
tains 0.488 mmol/g of alanine, meaning that the flux of
alanine is 0.488 μ mmol/g/h in our model, and one Bla
contains 28 alanine residues. Therefore,
Depending on the specified values of α and f in a particu-
lar model, rBla will be constrained by making either Equa-
tion (5) or (6) active. If α  is small enough that Bla
production does not reach the upper bound established
by f, then Equation (5) is active. This leaves Bla produc-
tion linearly proportional to plasmid production, mean-
ing that by maximizing plasmid production, Bla
production is concomitantly being maximized. If, on the
other hand, α is large enough such that the limit imposed
by f is hit, then Equation (6) is employed in lieu of Equa-
tion (5). That is,
where Equation (6) has been rearranged, and α* denotes
the value of α  where Bla production exactly equals f,
which can be determined using the results in Fig. 3A (black
solid line). Equation (7) makes Bla production a fixed
drain on resources when α ≥ α*, meaning that Bla is no
longer being simultaneously maximized with plasmid
production. Sub-maximal Bla production means that a
greater amount of resources are available for plasmid pro-
duction.
As an example, assume that the upper limit for Bla pro-
duction is 20% of total protein (f = 0.20), a value that, as
stated previously, is not uncommon for marker produc-
tion when copy numbers are high [27,28]. According to
Fig. 3A, when α* = 24, the 20% limit is reached. Hence,
when modeling how the maximum plasmid yield varies
with α for this case, Equation (7) can be employed with
the appropriate α*. The result is shown in Fig. 3A (red
dashed line), along with six other cases of f (black dashed
lines). In each case, the maximum plasmid yield varies
with α along the solid line until its respective value of α *.
Thereafter, Bla production is at its imposed limit, and the
maximum achievable plasmid yield becomes independ-
ent of α. In the f = 0.20 case, this means that E. coli can the-
oretically yield 377 mg/g of plasmid in addition to
expressing the marker at 20% of total protein if α ≥ α*.
Because Bla production becomes a fixed load for a given f
when α ≥ α*, the flux distribution for any α in that span
is identical. Figure 2 (bottom) shows the f = 0.20 flux dis-
tribution when α = 250 for comparison to the previously
described cases where no limit was imposed on Bla pro-
duction and α = 0 (top) or α = 250 (middle). As mentioned
previously, in the case of non-limited Bla production and
α = 250, the attainable plasmid yield falls from its abso-
lute maximum of 502 mg/g (α = 0) to 110 mg/g due to the
large amount of concomitant marker synthesis (44% of
total protein). When marker synthesis is instead limited to
20% of total protein, the increased availability of
resources that would otherwise go to marker production
are instead channelled into additional plasmid synthesis.
This allows for a substantially higher maximum plasmid
yield of 377 mg/g. Such an effect, as demonstrated here
for increased plasmid yield with decreased marker pro-
duction, has also been observed experimentally for
recombinant protein production, where 2-fold greater
yields were achieved when marker synthesis was signifi-
cantly decreased by employing a weakened promoter
[27].
Regarding key fluxes, as with the two previous cases, no
acid by-products are formed, and there is nil Pyk flux (Fig.
2, bottom). In fact, unless constrained to be nonzero, these
two fluxes always adopt a value of zero when the model's
objective is to maximize plasmid production, regardless
of the value of α and/or the imposition of an upper bound
on Bla production.
Effects of Pyruvate Kinase Flux and Acetate Production
In practice, wild-type E. coli produces acidic by-products
(usually acetate) [31], and its Pyk flux is nonzero due to
the presence of two Pyk isozymes [32]. Thus, achieving
flux distributions like the ones shown in Fig. 2 would be
unlikely without using metabolic engineering. To bench-
mark the wild-type and thus the gain provided by meta-
bolic engineering, the model can be used to predict how
maximum plasmid yield varies as a function of both ace-
tate and Pyk fluxes. To pursue this sensitivity and bench-
marking analysis, the following two constraints were
added to the model:
where β and φ are constants that relate glucose uptake to
acetate flux and Pyk flux, respectively. Whereas in all pre-
viously-discussed models these two fluxes were not con-
strained, the addition of Equations (8) and (9) enables
them to be constrained for any (β, φ) combination that
results in a feasible solution. Figure 4A shows how maxi-
mum plasmid yield varies over feasible (β, φ) combina-
tions (i.e. feasible combinations of racetate and rPyk) when α
= 250. Figure 4B shows the concomitant Bla production,
and Figures 4C–F show how other key fluxes vary to help
permit such plasmid and Bla production.
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rr acetate glucose = β (8)
rr Pyk glucose = φ (9)Microbial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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According to Fig. 4A, the greatest achievable yield (112
mg/g) arises when both racetate and rPyk are nil, which is in
agreement with earlier results (Fig. 2, middle) where the
model adopted values of zero for these fluxes when they
were left unconstrained. For any (racetate, rPyk) combination
where at least one of the fluxes is constrained to be
nonzero, the yield decreases from the 112 mg/g value. In
fact, the yield results fall into two regions, indicated by
Planes A and B (Fig. 4A). In each regime, the yield
decreases as either of the two fluxes are increased. For the
(racetate, rPyk) pairs that make up Plane A, this decrease in
yield is much steeper when rPyk is increased for fixed racetate
than when racetate is increased for fixed rPyk. In fact, the mag-
nitude of the slope in the former case is more than five-
times that in the latter, indicating that Pyk exhibits the
more dominant effect in this regime. The opposite is true
for the (racetate, rPyk) pairs that make up Plane B. There,
increasing racetate for fixed rPyk causes a sharp decrease in
yield, whereas yield remains nearly constant when rPyk is
increased for fixed racetate. The differing trends in Planes A
and B arise from how Ppc, malate dehydrogenase (Mdh),
and Mez are used in each (Fig. 4D–F). For all flux distribu-
tions in Plane A, Mdh is never operated in the reverse
direction (i.e. rMdh > 0), and Mez is always inactive (i.e. rMez
= 0). In the Plane B distributions, the reverse is true – Mdh
is always operated in reverse, and Mez is always active.
Here,  rPyk is not high enough to provide the necessary
pyruvate for meeting the specified racetate. Thus, additional
pyruvate is created by a cycle that uses increased rPpc,
reverse rMdh, and nonzero rMez. On the edge shared by
Planes A and B, rPyk is exactly high enough such that ace-
tate, plasmid, and marker are produced with nil flux
through Mez (Fig. 4E) and Mdh (Fig. 4F). In practice, Mez
flux is small, if present at all, and Mdh is not operated in
reverse during aerobic growth on glucose [20]. If the Ppc-
Mdh-Mez cycle were prevented from operating, either by
constraining rMdh > 0 or rMez = 0, then the model would be
Effects of Pyk flux and acetate by-production on maximum plasmid yield and other key fluxes Figure 4
Effects of Pyk flux and acetate by-production on maximum plasmid yield and other key fluxes. The model was 
run for different constrained combinations of racetate and rPyk in Equations (8) and (9), with α = 250 in Equation (5) and rtranshydro-
genase = 0 in every case. Specific (racetate, rPyk) zones are drawn in each panel for JM101 (wild-type) and PB25 (pykF pykA) based on 
experimentally determined ranges. On all plots, JM101 and PB25 operating regions are shown by a white zone and a thick black 
line, respectively. (A) Maximum plasmid yield. Plasmid-producing results fall into two regions, Planes A and B, whose character-
istics are discussed in the text. (B) Bla marker production. (C) HMP:glycolysis flux ratio. (D) Ppc flux as % glucose uptake. (E) 
Mez flux as % glucose uptake. (F) Mdh flux as % glucose uptake, where the white line is the locus of solutions where Mdh flux = 
0.Microbial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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infeasible for the (racetate, rPyk) pairs that constitute Plane B,
leaving only Plane A.
Yield Horizons of Mutant and Wild-type E. coli JM101
The preceding results indicate that the highest plasmid
yields are attained when the Pyk and acetate fluxes are
zero (Fig. 2 and Fig. 4A). Mutants exist that approach such
attributes. In this section, the yield horizons of one
mutant and its wild-type are determined, and then con-
trasted to each other and the best maximal yields.
An E. coli mutant that has the activity of the two Pyk iso-
zymes abolished has been constructed and denoted as
strain PB25 [33]. Many of the characteristics of PB25 and
its wild-type parent JM101 have been well established
[19,20,33-37]. Several reports indicate that PB25 pro-
duces considerably less acetate than JM101 during batch
growth in glucose minimal medium. At high glucose (10
g/L), Zhu et al. [19] found that acetate production occurs
with a stoichiometry of β = 0.25 and 0.75 for PB25 and
JM101, respectively. In terms of a carbon balance, this
means that JM101 wastes 25% of input carbon as acetate,
whereas PB25 wastes only 8%. At 2 g/L glucose, Ponce
[34] reported β = 0.33 for PB25 and 0.46 for JM101. Addi-
tionally, Flores et al. [20] data indicate that β = 0.55 for
JM101 when grown on 3 g/L glucose.
Concerning Pyk, φ = 0 for PB25, as its Pyk activity has been
eliminated [33]. For JM101, Flores et al. [20] measured φ
= 0.41. Also, Emmerling et al. [36] found φ = 0.19 for
JM101 grown in a chemostat operated at a dilution rate of
0.40 h-1 with 3.6 g/L glucose.
Based on these reported experimental values, approxi-
mate (racetate, rPyk) flux regimes for each strain have been
highlighted in the results of Fig. 4 (α = 250). As this sen-
sitivity analysis shows, even if racetate and rPyk are allowed to
vary somewhat, the deletion of the two Pyk isozymes in
PB25 permits it to attain substantially higher plasmid
yields than JM101 (Fig. 4A). PB25 accomplishes this by
changing the cell's stoichiometry such that it is better-
positioned for plasmid production in three ways: (i) a
large rHMP/rglycolysis flux ratio (Fig. 4C), (ii) low acetate pro-
duction, and (iii) a higher Ppc flux, with no Mez nor
reverse Mdh activity needed (Fig. 4D–F).
Figure 5 shows the contrast in flux distributions between
PB25 (bottom) and JM101 (top) in greater detail. Here, val-
ues of (β, φ) were selected for each strain that fell within
their respective experimental ranges. That is, (β, φ) = (0.3,
0) for PB25 and (0.5, 0.3) for JM101, hereafter referred to
as the PB25 model and the JM101 model, respectively. In
addition, the earlier version of the model, where the ace-
tate and Pyk fluxes were left unconstrained, will be
referred to as the unconstrained model. As shown in Fig. 5,
compared to JM101, PB25 produces 4-fold more plasmid
(99 vs. 25 mg/g) and concomitantly 2.7-fold more Bla
marker (41 vs. 15% total protein). PB25 does this, in part,
by maintaining a higher rHMP/rglycolysis flux ratio (3.3 vs.
0.81) (see also Fig. 3E). Furthermore, PB25 wastes 40%
less carbon as acetate, and it also wastes less in the form of
CO2 despite the higher HMP flux (205 vs. 144). The
higher CO2 levels of JM101 arise partially due less Ppc flux
(30 vs. 21) (see also Fig. 3F) but predominantly due to
higher pyruvate dehydrogenase (109 vs. 71) and TCA
cycle (40 vs. 20) fluxes, which are brought about by its
considerable Pyk activity. Overall, the PB25 model's flux
distribution more closely matches that of the highest plas-
mid-producing unconstrained model (Fig. 2, middle).
To contrast the models at other levels of marker expres-
sion (i.e. besides α = 250), the PB25 and JM101 models
can be solved at various values of α, as was done already
for the unconstrained model (Fig. 3A, E, F). Figures 3B
and 3C show how maximum plasmid yield varies with α
for the JM101 and PB25 models, respectively. For every α,
the low acetate and nil Pyk phenotype of PB25 endows it
with a substantial advantage in terms of plasmid produc-
tion as compared to the wild-type by enabling an rHMP/rgly-
colysis flux ratio (Fig. 3E) and Ppc flux (Fig. 3F) that are
closer to the unconstrained model. When no marker is
produced (α = 0), the maximum capacity of the mutant is
about 4-fold greater (443 vs. 110 mg/g) than the wild-
type. When Bla production is limited, the advantage of
PB25 over JM101 widens further. For example, when (f =
0.20, α* = 28) in Equation (7) for the PB25 model, the
maximum yield is 318 mg/g for all α ≥ 28. In contrast, the
JM101 model is unable to produce Bla at 20% of total pro-
tein even at infinite α. In fact, even when α  = 1000
(roughly half that of fully active LacZ production [21,22]),
plasmid and marker production are 7.4 mg/g and 17.1%
of total protein, respectively. Interestingly, these wild-type
values for yield and marker production (Fig. 3C) are on
par with those that have been observed experimentally.
For example, Rozkov et al. [28] determined that the kan-
amycin resistance marker is present at 18% of total pro-
tein while the pUC-type plasmid yield was 4.9 mg/g.
Effects of Transhydrogenase Activity
In all models considered thus far, the production of
NADPH for biosynthetic reducing power has occurred via
(i) two reactions in the oxidative HMP pathway, (ii) one
reaction in the TCA cycle, and (iii) a small additional con-
tribution if there is flux through the NADP-dependent
Mez (Fig. 1, red font). These reactions must generate
enough NADPH to meet not only that required for basal
biomass demand, but also that required for plasmid and
marker synthesis. As a result, the NADPH constraint (see
Methods) has a significant impact on the resulting fluxMicrobial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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Maximum plasmid-producing flux distributions for the JM101 and PB25 models Figure 5
Maximum plasmid-producing flux distributions for the JM101 and PB25 models. For both distributions, α = 250 in 
Equation (5), and rtranshydrogenase was constrained to zero. Equations (8) and (9) were employed to constrain racetate and rPyk to 
experimental values for JM101 (wild-type) and PB25 (pykF pykA). Top: JM101. Bottom: PB25. For simplicity, the network in Fig. 1 
has been condensed and fluxes (mmol/g/h) have been expressed as % of glucose uptake, except rBla (expressed as % of total 
protein) and rplasmid (expressed as yield in mg/g). The production of lactate and succinate have also been omitted, as these fluxes 
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distributions. Indeed, a characteristic of high plasmid-
producing solutions is high HMP flux (Fig. 4C).
In practice, NADPH may also be supplied via a nicotina-
mide nucleotide transhydrogenase, which catalyzes the
interconversion of NADH and NADPH (Fig. 1). Such
interconversion would relax somewhat the constraint that
NADPH production imposes on the network. E. coli pos-
sesses two transhydrogenases, PntAB and UdhA. PntAB is
membrane-bound, translocates a proton, and operates in
the direction that reduces NADP+ from NADH, whereas
UdhA is soluble, energy-independent, and operates in the
direction that oxidizes NADPH to form NADH [38]. It has
been estimated that PntAB contributes 35–45% of the
NADPH needed for biomass synthesis during aerobic
batch growth with glucose, whereas UdhA is only needed
under conditions of excess NADPH [38].
In each model thus far, transhydrogenase activity has been
constrained to be inactive. Therefore, to examine its effect
on plasmid production, this constraint was relaxed and
given an upper bound set to 40% of NADPH biomass
demand, based on the experimental value of Sauer et al.
[38]:
This relaxed transhydrogenase constraint was incorpo-
rated into the PB25 and JM101 models, as well as into the
unconstrained model. For all α in each model, gains in
plasmid production resulted when the transhydrogenase
was allowed to be active (Fig. 3D). In the unconstrained
model, plasmid production increased by 18% at each α
when the transhydrogenase was active. In the PB25
model, the gain improved to 20% for each α. For JM101,
the effect of an active transhydrogenase is even greater,
with gains of over 82% resulting. When no resources are
lost to marker production (i.e. α = 0), specific plasmid
yield reaches 200 and 533 mg/g in the JM101 and PB25
models, respectively. In the unconstrained model, it
reaches 592 mg/g, which is the highest value found in this
analysis.
How transhydrogenase activity improves plasmid yield
can be gleaned from contrasting the flux distributions for
the PB25, JM101, and unconstrained cases. These are
shown in Figure 6 (left column) for α = 250 alongside their
respective distributions that resulted when the transhy-
drogenase was constrained to be inactive (right column;
copied from Fig. 2 and Fig. 5). While the JM101 model
showed the greatest percent improvement to plasmid pro-
duction, as mentioned previously, the absolute gains in
plasmid yield were about the same in all three models at
roughly 20 mg/g. Gains in plasmid and concomitant
marker production necessitate increased precursor usage,
leaving less carbon to be given off as CO2 and requiring
more ATP and NADPH. Because a significant amount of
NADPH is produced by the transhydrogenase in these
models (i.e. the upper bound is hit in each model), less
NADPH needs to be produced elsewhere. Consequently,
lower fluxes should be expected through the oxidative
HMP pathway and/or isocitrate dehydrogenase. Indeed,
while each model shows about the same flux through iso-
citrate dehydrogenase relative to their respective inactive
transhydrogenase case, each exhibits significantly
decreased oxidative HMP pathway usage (see also Fig. 3E
for additional α). This allows a significantly greater frac-
tion of input carbon to directly enter glycolysis, with the
ultimate effect being a greater supply of precursor metab-
olites downstream of GAP that can be directed to plasmid
and Bla synthesis. Moreover, decreased oxidative HMP
flux, increased Ppc flux (see also Fig. 3F for additional α),
and less-than-or-equal-to pyruvate dehydrogenase and
TCA fluxes collectively mean that less carbon is lost as
CO2, which further favors plasmid and Bla production.
Discussion
Through flux analysis, the capacity of E. coli for producing
plasmid was investigated. Acetate production and the con-
stitutive expression of the plasmid's antibiotic resistance
marker were found to exert negative effects, while low Pyk
flux and the generation of NADPH by transhydrogenase
activity enhance yield. The highest theoretical yield (592
mg/g) resulted under conditions of no marker or acetate
production, nil Pyk flux, and the maximum allowable
transhydrogenase activity (Fig. 3D, dashed black lineat α =
0). Such a yield is 12-fold higher than the best reported
value [8], which suggests that strain engineering can be
done to potentially elevate yield further. The lowest
potential yields resulted when Pyk and acetate fluxes were
constrained to wild-type levels (Fig. 3B and Fig. 4A). Fur-
ther, these predicted levels of yield (on the order of tens of
mg/g) and concomitant marker production (10–18% of
total protein) are comparable to those reported experi-
mentally [28].
These results and conclusions, however, should be consid-
ered in terms of the limitations of flux models and con-
trasted further to existing experimental results. When one
conservatively views the predictions of flux models, they
can be viewed as indicating the best a cell can do given (i)
the constraints imposed, (ii) the nature of the nested met-
abolic reactions, and (iii) the competing demands on
resources that occur given that some beneficial redun-
dancy exists, such as multiple points for NADPH genera-
tion. Regulation and other limitations are typically not
considered. In this case, one major assumption was that
plasmid replication was constrained more by precursor
supply than by the negative control over replication fre-
quency or DNA polymerase activity.
rtranshydrogenase ≤ 04 0 1 82 2 5 .( . )    μ (10)Microbial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
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Effects of transhydrogenase activity on maximum plasmid-producing flux distributions Figure 6
Effects of transhydrogenase activity on maximum plasmid-producing flux distributions. For all distributions, α = 
250 in Equation (5). Left column:rtranshydrogenase limited to 40% of NADPH biomass demand as per Equation (10). Right column:rtran-
shydrogenase constrained to zero; these distributions were copied from Fig. 2 and Fig. 5 to facilitate comparisons. In Equations (8) 
and (9), racetate and rPyk were: unconstrained (top row), set to wild-type JM101 values (middle row), or set to Pyk-deficient PB25 
values (bottom row). For simplicity, the network in Fig. 1 has been condensed and fluxes (mmol/g/h) have been expressed as % 
of glucose uptake, except rBla (expressed as % of total protein) and rplasmid (expressed as yield in mg/g). The production of lactate 
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We suggest that such a limitation does not necessarily
negate the value of predictions from flux models. Rather,
if the aim is to alter cells through extensive metabolic
engineering, then it seems useful to have the best yield
and target flux distribution identified ahead of time.
Knowing whether current yields already approach the the-
oretical yield is worthwhile because it indicates that
research resources can be better directed elsewhere. On
the other hand, when the yield horizon is promising, the
optimal flux distribution provides the ultimate target for
the mutagenesis tasks.
Prior work also suggests that informative and imple-
mentable results are often attained. One example is pro-
vided by the metabolic engineering of B. subtilis for the
purpose of producing more folic acid. Flux analysis pre-
dicted that suppressing Pyk activity was amongst the
attributes of an optimal flux distribution. Subsequent
experimentation determined that this mutation, in con-
junction with others, increased the folic acid titer by 700%
[15].
To scrutinize further the predictions reported here, a com-
parison to prior work on E. coli expressing high copy
number plasmids can be made. Here, how adaptations
compare to the trends in the optimal flux distributions
can provide an indication of the reasonableness of the
optimal trends. In one study, E. coli JM101 grown in M9
minimal medium containing glucose (i.e. the same strain
and growth conditions modeled in this study) exhibited
less growth rate burden from plasmid maintenance when
the HMP pathway gateway enzyme, glucose-6-phosphate
dehydrogenase (Zwf) was over-expressed [39]. Transfor-
mation with a multicopy plasmid resulted in a growth rate
decrease from 0.70 to 0.46 h-1; the growth rate recovered
to 0.57 and 0.64 h-1, however, when Zwf activity increased
9- and 12-fold, respectively [39]. In another study, Ow et
al. [40] found that when E. coli DH5α harbored a high
copy plasmid, expression from zwf increased by 1.2-fold,
while expression from phosphoglucose isomerase
decreased by 1.8-fold. Provided that flux correlates with
expression level, their results suggest that one adaptation
to plasmid presence entails increasing the rHMP/rglycolysis
ratio by about a factor of 2. Lastly, Birnbaum and Bailey
[41] reported that E. coli contained significantly less Pyk
and significantly more Ppc when copy number increased.
The optimal rHMP/rglycolysis ratio, in turn, was predicted to
range from roughly 1 to 2, where the particular value
depends on the transhydrogenase activity (Fig. 3E, black
lines). This optimal value of the ratio is 3.5- to 7-fold
greater than the experimentally observed wild-type JM101
value of 0.29 [20]. In the optimal solutions, the Ppc flux
is much greater than that of Pyk regardless of transhydro-
genase activity (Fig. 3F, black lines). Indeed, the best plas-
mid-producing solutions show nil Pyk activity. In
contrast, Ppc flux has been measured to be only 60% that
of Pyk for wild-type JM101 [20], a feature which was also
captured reasonably well by the JM101 model (Fig. 5, top;
70%). Overall, the trends in the optimal flux solutions
thus both track and combine the HMP/glycolysis, Pyk,
Ppc, and other flux adaptations reported to occur when
high copy number plasmids are maintained.
Thus, the match between the trends in the optimal flux
distributions and experimental results raises the prospect
that the particular flux values can serve as useful guide-
posts. Furthermore, suppressing Pyk activity appears to be
a key facet of the optimal solutions. Abolishing Pyk pro-
vides a hard constraint that alters cellular stoichiometry
such that Ppc and HMP fluxes are forced to increase, while
acetate formation is suppressed. These changes provide
improved precursor supply for plasmid and concomitant
marker synthesis, as well as ensure that the necessary
NADPH production occurs. These features also can be
viewed as "bundling" the individually observed adapta-
tions described above for maintaining high copy number
plasmids.
To experimentally explore the prediction that abolishing
Pyk activity leads to flux changes that can increase plasmid
yield, we recently compared and reported the plasmid
copy numbers attained by JM101 and PB25 [16]. These
copy numbers were obtained for pGFPuv (i.e. the same
model plasmid used in this theoretical analysis) during
exponential growth in glucose minimal medium. Because
pGFPuv employs a temperature-sensitive pUC ori, the
copy numbers were measured in cells growing isother-
mally at 37°C as well as in cells that were shifted from 37
to 42°C, where copy number typically increases 2- to 3-
fold over several generations [2,5,7,10,11], as mentioned
previously.
When grown at 37°C, PB25 maintained a 4-fold higher
copy number than JM101. After being temperature-
shifted, PB25 contained over 9-fold more plasmid than
isothermally-grown JM101. Furthermore, when the
strains are compared on a temperature-shifted basis, the
copy number attained by JM101 was less than half that
attained by PB25, whose copy number at 42°C reached
over 1200. Overall, PB25 was found to contain consider-
ably more plasmid than JM101, while PB25 maintained
78 and 92% of the specific growth rate of JM101 at 37 and
42°C, respectively. The comparable growth rates indicate
that growth rate changes alone cannot account for the sig-
nificantly different plasmid contents. Moreover, after the
temperature shift, new plateau levels of plasmid/cell were
attained after about three generations, indicating that bal-
anced growth was achieved by each strain and that each
exhibited significantly different rates of plasmid synthesis.Microbial Cell Factories 2009, 8:27 http://www.microbialcellfactories.com/content/8/1/27
Page 15 of 17
(page number not for citation purposes)
Based on the modeling results, we interpret the experi-
mental results described above as follows. Increasing tem-
perature increased the copy number in both JM101 and
PB25 to new plateaus; hence, negative control over plas-
mid replication remains a factor in pUC-type plasmids.
However, when grown at 42°C, PB25 maintained a
growth rate similar to JM101 despite possessing much
more plasmid and comparable or more marker synthesis.
Thus, as suggested by the modeling, PB25 possesses a flux
distribution that enables extra DNA and marker synthesis
to be better tolerated while significant cell growth still
occurs. These conclusions then suggest that diminishing
negative control further in a metabolic background pro-
vided by PB25 may further increase the copy number. An
approach such as that described by Tomizawa [42] could
potentially be used to introduce additional ori mutations
that might further weaken negative control beyond the
level already provided by the rop  and pUC mutations,
bearing in mind that additional non-ori sequence-specific
effects may also prove beneficial [8]. Additionally, yield
enhancements might result with the over-expression or
deletion of other key proteins involved in plasmid replica-
tion. However, Williams et al. [8] have demonstrated that
this is not the case after examining a number of such rep-
lication factors. Finally, maintaining a similar growth rate
despite increased plasmid content suggests that DNA
polymerase activity does not yet present a limit. That is, if
total DNA polymerase activity was significantly taxed, one
would expect that the time required for chromosomal
DNA replication, and thus the cell cycle time, would have
lengthened considerably.
Conclusion
The capacity of E. coli for producing plasmid DNA was
examined using metabolic flux analysis, and factors were
identified that significantly influence specific yield. Both
the production of acetate and the plasmid-encoded anti-
biotic resistance marker negatively impact plasmid pro-
duction, whereas transhydrogenase activity and low/nil
Pyk flux offer positive effects. The highest theoretical yield
(592 mg/g) resulted under conditions of no acetate or
marker production, nil Pyk flux, and maximum transhy-
drogenase activity. As this yield is 12-fold higher than the
best reported to date, it implies that metabolic engineer-
ing of the host strain background might aid in narrowing
the gap between the theoretical yield and the achievable
yield. One model-based mutation, the deletion of Pyk,
has been explored experimentally. In glucose minimal
media, it produced substantially more plasmid DNA than
the wild-type with only a modest penalty to growth rate,
thus corroborating the model predictions.
Additional strain engineering strategies suggested by the
model include transhydrogenase up-regulation and mini-
mization of marker expression, or perhaps a shift away
from selection via antibiotic resistance all together. A prec-
edent has already been established in the former case,
where transhydrogenase over-expression has helped to
increase the productivity and yield of poly(3-hydroxybu-
tyrate) [43]. Weakening marker expression or using an
alternative means of selection have also been explored by
other groups, mainly to avoid patient safety issues associ-
ated with the presence of the marker in the final formula-
tion [44]. Here, we have demonstrated theoretically that
minimization/elimination of marker synthesis also offers
the added benefit of freeing up resources that can be chan-
nelled into additional plasmid output.
Appendix
Estimation of Maximum Theoretical Plasmid Yield via 
Simple Carbon Balance
For the case of growth on minimal glucose medium, car-
bon enters the cell as either glucose or CO2. This carbon is
used to produce biomass, and it is also given off as CO2
and excreted as acid by-products (e.g. acetate, lactate, suc-
cinate). When replicating a plasmid and constitutively
producing its antibiotic resistance marker, carbon must
also be used for these two species. This gives the following
overall carbon balance reaction:
where CO2 is located on the right-hand side to reflect its
net production.
The amount of input carbon (mmol carbon/g) from glu-
cose equals 95.2 based on its molecular weight, the fact
that there are six carbons per glucose, and that 0.35 g/g
glucose is a typical biomass yield for aerobic growth in
glucose minimal medium [19]. The amount of carbon in
biomass is 43.2, which was calculated based on the
required amounts of precursor metabolites [17] and their
respective amounts of carbon per metabolite. This con-
sumes approximately 45% of the input carbon. If we
assume that, say, 30% is given off as CO2, this leaves 25%.
If we further assume (i) that all of this remaining carbon
is put toward plasmid production, instead of lost as acid
by-products, and (ii) that we neglect marker production,
then the maximum attainable plasmid yield for a model
plasmid, pGFPuv, is 742 mg/g. This number was arrived
at using the chemical formula of pGFPuv
(C65131H75142O40044N24968P6674) and its corresponding
molecular weight. For the 3337-bp pGPFuv plasmid, this
yield corresponds to roughly 33,300 copies/cell. This plas-
mid was chosen because it is pUC-based, commercially
available, and contains a gfpuv gene that acts as a dummy
therapeutic gene sequence.
glucose biomass CO acids plasmid marker →+ + ++ 2
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Abbreviations
αKG: α-ketoglutarate; μ: specific growth rate (h-1); 2PG: 2-
phosphoglycerate; 3PG: 3-phosphoglycerate; 6PG: 6-
phosphogluconate; 6PGL: 6-phosphogluconolactone;
AcCoA: acetyl-coenzyme A; Ac-P: acetyl-phosphate; Bla: β-
lactamase; BPG: 1,3-bisphosphoglycerate; CIT: citrate;
dATP: deoxyadenosine triphosphate; dCTP: deoxycyto-
sine triphosphate; dGTP: deoxyguanosine triphosphate;
DHAP: dihydroxyacetone phosphate; dNTP: deoxyribo-
nucleoside triphosphate; dTTP: deoxythymidine triphos-
phate; F6P: fructose-6-phosphate; FBP: fructose-1,6-
bisphosphate; FUM: fumarate; G6P: glucose-6-phosphate;
GAP: glyceraldehyde phosphate; HMP: hexose mono-
phosphate pathway; IC: isocitrate; LacZ: β-galactosidase;
MAL: malate; Mdh: malate dehydrogenase; Mez: malic
enzyme(s); OAA: oxaloacetate; ori: origin of replication;
PEP: phosphoenolpyruvate; Ppc: phosphoenolpyruvate
carboxylase; PTS: phosphotransferase system; Pyk: pyru-
vate kinase; PYR: pyruvate; R5P: ribose-5-phosphate; ri:
flux of i (e.g. rPyk is the flux of pyruvate kinase); Ru5P: rib-
ulose-5-phosphate; S7P: sedoheptulose-7-phosphate;
SUC: succinate; Succ-CoA: succinyl-coenzyme A; TCA: tri-
carboxylic acid cycle; X5P: xylulose-5-phosphate.
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